The latest market sizing information for 2023, projected up to 2032, is now incorporated into The Business Research Company’s comprehensive global market reports.

According to The Business Research Company’s Inotropic Agents Global Market Report 2023, the inotropic agents market is poised for substantial growth within the projected timeframe.

Key observations from the inotropic agents market forecast include:

1. Market Size:

The global inotropic agents market is anticipated to expand from $2.10 billion in 2022 to $2.32 billion in 2023, reflecting a compound annual growth rate (CAGR) of 10.88%. Projections suggest that the global inotropic agents market will attain a size of $3.56 billion by 2027, with a CAGR of 11.24%.

2. Major Driving Force:

The surge in the prevalence of cardiovascular diseases stands as a significant impetus propelling the inotropic agent market’s advancement. For example, as of October 2022, data shared by the Centers for Disease Control and Prevention—an American governmental agency—revealed heart diseases as the leading cause of death in the United States. In the year 2020, approximately 697,000 individuals succumbed to heart disease, accounting for roughly 1 in 5 deaths. Moreover, around 20.1 million adults were grappling with coronary artery disease. Each year, roughly 805,000 individuals in the US experience heart attacks. Furthermore, the American College of Cardiology projected an increase of 33.8 percent in stroke risk, estimating the number of stroke cases to rise to 15 million between 2025 and 2060. The prevalence of cardiovascular diseases thus propels the trajectory of the inotropic agent market.

View More On The Inotropic Agents Market Report 2023 – https://www.thebusinessresearchcompany.com/report/inotropic-agents-global-market-report

3. Notable Trend:

The approval of novel drugs represents a notable trend gaining traction in the inotropic agents market. Leading players within the market are dedicating their efforts to developing innovative products and medications to solidify their market standing. In a case in point, Bristol-Myers Squibb, a US-based pharmaceutical company, secured regulatory approval from the U.S. Food and Drug Administration (FDA) for Camzyos™ (mavacamten) in April 2022. This drug, aimed at treating class II-III obstructive hypertrophic cardiomyopathy (HCM), enhances functional capacity and alleviates symptoms. The medication’s mechanism involves inhibiting excessive heart muscle contraction by selectively targeting cardiac myosin, a protein vital for muscle contraction. It caters to individuals with symptomatic obstructive HCM who haven’t responded satisfactorily to alternative treatment options like beta-blockers or calcium channel blockers.

4. Dominant Region:

In 2022, North America emerged as the leading region in the inotropic agents market.

5. Key Industry Players:

Prominent entities in the inotropic agents market encompass Pfizer Inc., GSK PLC., Novartis AG, Mylan N.V., Boehringer Ingelheim International GmbH, AstraZeneca PLC., Johnson & Johnson, Bayer AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Cipla Ltd., Eli Lilly And Company, Sanofi S.A., Baxter International Inc., Hikma Pharmaceuticals PLC., Sun Pharmaceuticals Industries Ltd., and Cadila Pharmaceuticals Ltd.

Request A Sample Of The Global Inotropic Agents Market Report 2023:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10711&type=smp

Key Inotropic Agents Market Segments
1) By Type: Positive Inotropic Drugs, Negative Inotropic Drugs, Other Types
2) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
3) By Indication: Heart Attack, Heart Failure, Angina, Arrhythmia, Other Indications
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
5) By End User: Hospital, Homecare, Specialty Centers, Other End Users

The Inotropic Agents Global Market Report 2023  furnishes an in-depth analysis encompassing the inotropic agents market’s size, trends, drivers, opportunities, strategies, and company assessments. The countries featured in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, while the predominant seven regions encompass Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

View More Related Reports –
Generic Pharmaceuticals Global Market Report 2023
Pharmaceutical Drugs Global Market Report 2023
Branded Generics Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-mode